Literature DB >> 23509571

Atomoxetine and stimulant medications in children and adolescents with persistent symptoms of attention deficit hyperactivity disorder despite monotherapy.

Amanda Jacques.   

Abstract

Entities:  

Year:  2012        PMID： 23509571      PMCID： PMC3567577          DOI： 10.3821/145.5.cpj226

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  10 in total

1.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

2.  ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients.

Authors:  Julie A Dopheide
Journal:  Am J Health Syst Pharm       Date:  2005-07-15       Impact factor: 2.637

3.  The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.

Authors:  Steven R Pliszka; M Lynn Crismon; Carroll W Hughes; C Keith Corners; Graham J Emslie; Peter S Jensen; James T McCRACKEN; James M Swanson; Molly Lopez
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-06       Impact factor: 8.829

4.  Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?

Authors:  Helmut Niederhofer
Journal:  Psychiatr Danub       Date:  2009-09       Impact factor: 1.063

5.  Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.

Authors:  Sol Jaworowski; Fortu Benarroch; Varda Gross-Tsur
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-06       Impact factor: 2.576

6.  Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.

Authors:  Thomas E Brown
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

7.  An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.

Authors:  Paul Hammerness; Anna Georgiopoulos; Robert L Doyle; Linsey Utzinger; Mary Schillinger; Marykate Martelon; Kerry Brodziak; Joseph Biederman; Timothy E Wilens
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

8.  An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.

Authors:  Timothy E Wilens; Paul Hammerness; Linsey Utzinger; Mary Schillinger; Anna Georgiopoulous; Robert L Doyle; Marykate Martelon; Kerry Brodziak
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

9.  Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.

Authors:  Raveen Hanwella; Madhri Senanayake; Varuni de Silva
Journal:  BMC Psychiatry       Date:  2011-11-10       Impact factor: 3.630

10.  A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder.

Authors:  Gabrielle A Carlson; David Dunn; Douglas Kelsey; Dustin Ruff; Susan Ball; Lisa Ahrbecker; Albert J Allen
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2007-09-27       Impact factor: 3.033
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.